The contract manufacturing market for Pharmaceuticals in China is estimated to be worth USD 13 billion in 2030, predicts Roots Analysis

 

Owing to reasons, such as a booming economy and availability of skilled labor, outsourcing to Asian CMOs, primarily in China, is considered an attractive business model to pharmaceutical developers / sponsors, across the world

 

Roots Analysis is pleased to announce the publication of its recent study, titled, “China Pharmaceutical Contract Manufacturing Services Market, 2020-2030.”

 

The report features an extensive study of the current market landscape and future opportunities associated with the pharmaceutical contract manufacturing market in China. The study also features a detailed analysis, highlighting the capabilities of pharmaceutical CMOs in this region. Amongst other elements, the report features:

§  A detailed assessment of the current market landscape of pharmaceutical contract manufacturers in China engaged in the development of active pharmaceutical ingredients (APIs), intermediates and finished dosage formulations (FDFs). 

§  A detailed landscape of the pharmaceutical manufacturing facilities in China, including an analysis based on location of these facilities, highlighting key manufacturing hubs.

§  A brief discussion of various regulatory guidelines in China and various challenges, related to regulatory scrutiny, faced by pharmaceutical manufacturers in China.

§  Detailed profiles of key players that offer a diverse range of capabilities for the manufacturing of pharmaceutical products in China.

§  A review of the pharmaceutical manufacturing related initiatives of the top 10 big pharma players (shortlisted from the top companies of 2019 by revenues).

§  An analysis of the partnerships and acquisitions that have been established in this domain, in the recent past.

§  A detailed capacity analysis based on the installed reactor capacities of the manufacturing facilities in China.

§  A case study comparing the key characteristics of large molecule and small molecule drugs, along with details on the various steps involved in their respective manufacturing processes.

§  A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)

§  Key Geographical Regions

  • Eastern China
  • Southern China
  • Northern China 

 

§  Type of Product

  • Active Pharmaceutical Ingredients (APIs)
  • Drug Products

 

§  Type of Drug Product

  • Solid
  • Liquid / Semi-Solid
  • Injectable
  • Others

 

§  Scale of Operation

  • Clinical
  • Commercial

 

§  Company Size

  • Small
  • Mid-Sized
  • Large / Very Large

 

 

Key players covered in the report

§  2Y-Chem

§  Aurisco Pharmaceutical

§  ChemPartner

§  Dorrapharma

§  Hubei Biocause Pharmaceutical

§  Infoark

§  Ningbo Menovo Pharmaceutical

§  Shandong Xinhua Pharmaceutical

§  Shanghai Acebright Pharmaceuticals

§  STA Pharmaceutical

§  Zhejiang Huahai Pharmaceutical

 

For more information please click on the following link:

https://www.rootsanalysis.com/reports/view_document/china-pharmaceutical-contract-manufacturing/312.html

 

Other Recent Offerings

1.     China Biopharmaceutical Contract Manufacturing Market, 2020 – 2030

2.     HPAPI and Cytotoxic Drugs Manufacturing Market (3rd Edition), 2020-2030

3.     Novel coronavirus (COVID-19): Preventive Vaccines, Therapeutics and Diagnostics in Development

 

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

 

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

ben.johnson@rootsanalysis.com

Facebook - https://www.facebook.com/RootsAnalysis

LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/

Twitter - https://twitter.com/RootsAnalysis

Comments

Post a Comment

Popular posts from this blog

A relatively larger proportion of these firms are headquartered in the US, claims Roots Analysis

  Lately, drug manufacturers have started showing evident interest in modular facilities and using modularity in design approaches owing to the amplified value of smaller production facilities, which are more efficient and flexible. The increased demand for multi-product, multi-purpose, smaller batch size facilities has also prompted equipment manufacturers to revisit their product offerings.   To order this 300+ page report, which features 120+ figures and 130+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/modular-facilities-flexible-drug-manufacturing-platforms-of-the-future/178.html   The USD xx billion (by 2030) financial opportunity within the modular facilities market has been analyzed across the following segments: ·        Type of Modular Construct  §   Hybrid Skid §   Plug-and-Play §   Skid-Mounted §   Truckable §   Others §   Type of Construc...
Read more

The subcutaneous biologic drugs and affiliated technologies market is projected to be worth over USD 180 billion by 2030

    Subcutaneous drug delivery, given the use of tailored formulation development solutions, has brought about a paradigm shift in at-home healthcare, enabling users to administer (life-saving) medications without having to rely on medical professionals   Roots Analysis is pleased to announce the publication of its recent study, titled “ Subcutaneous Biologics, Technologies and Drug Delivery Systems (3rd Edition), 2020-2030 ” report to its list of offerings.   The report provides a detailed study on the current market landscape and future potential of biologics designed for subcutaneous administration. In addition, the study provides an in-depth analysis of the formulation technologies and drug delivery systems (focusing on large volume wearable injectors, autoinjectors, pen injectors, needle-free injectors, drug reconstitution systems, prefilled syringes and implants) that enable subcutaneous delivery of the biologic drugs. Amongst other elements, the r...
Read more

PRE-INSTALLED SINGLE-USE SENSORS FOR BIOPROCESSING-CASE STUDY

    During our research, we identified 31 pre-installed single-use sensors developed by various companies for bioprocessing. The current market landscape is predominantly characterized by the presence of large (38%) and small (37%) players. Notable examples of large players in this domain include ( in alphabetical order ) Cytiva Life Sciences (US), Hamilton (US) and Pall (US).   To Request Sample Pages -: https://www.rootsanalysis.com/reports/single-use-sensors-for-bioprocessing.html       Majority of the pre-installed single-use sensor systems are designed for both, research and biomanufacturing purposes. This is followed by those designed for only research purposes. Notable examples of products which are developed for both research and biomanufacturing applications, include ( arranged alphabetically ) ÄKTA ready XL sensor technology (Cytiva Life Sciences), Allegro™ MVP Single-Use System (Pall Corporation) and FUTURA pico (Aber Instruments)...
Read more